List All Phase 1 Studies

SCCA Clinical Studies: Phase I Program

 

PARP Inhibitor ABT-888 with Cisplatin and Vinorelbine (7161)
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Investigator: Eve Rodler, MD;   Conditions: Advanced Breast Cancer;    Status: Closed;   Study ID: NCT01104259

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

GA101 (RO5072759) for Previously Untreated Chronic Lymphocytic Leukemia (2514)
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Investigator: Ajay K. Gopal, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01300247

LY2157299 for Metastatic Cancer and Advanced or Metastatic Pancreatic Cancer
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

Investigator: Andrew Coveler, MD;   Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer;    Status: Closed;   Study ID: NCT01373164

Dose-Escalation Study of MLN9708 (C16001) (UW08039)
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies

Investigator: John Thompson, MD;   Conditions: Advanced Non-Hematologic Malignancies, Non Small Cell Lung Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Prostate Cancer;    Status: Closed;   Study ID: NCT00830869

SGN-75 + Everolimus for Metastatic Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

Investigator: John A. Thompson, MD;   Conditions: Renal Cell Carcinoma;    Status: Closed;   Study ID: NCT01677390

Recombinant Interleukin-15 in Treating Patients With Advanced Solid Tumors
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

Investigator: John A. Thompson, MD;   Conditions: Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01727076

PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Closed;   Study ID: NCT01839487

SGN-LIV1A for Breast Cancer (13038)
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01969643

BMS-986016 for Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas (13045)
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Investigator: Ajay K. Gopal, MD;   Conditions: Hematologic Neoplasms;    Status: Recruiting;   Study ID: NCT02061761

MEDI0680 (AMP-514) With MEDI4736 for Advanced Malignancies
A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies

Investigator: Laura Chow, MD ;   Conditions: Advanced Malignancies;    Status: Recruiting;   Study ID: NCT02118337

ME-344 in Combination With Hycamtin® for Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors

Investigator: Barbara A. Goff, MD;   Conditions: Solid Tumors;    Status: Closed;   Study ID: NCT02100007

MGCD516 for Advanced Solid Tumor Malignancies (20150094)
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Investigator: Keith Eaton, MD, PhD;   Conditions: Solid Tumors;    Status: Recruiting;   Study ID: NCT02219711

SGN-CD19B for B-Cell non-Hodgkin lymphoma (20160030)
A phase 1, open-label, dose-esclation study of SGN-CD19B in patients with relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma

Investigator: Stephen Smith, MD;   Conditions: Lymphoma; Non-Hodgkin (NHL); Lymphoma, Large B-Cell,;    Status: Recruiting;   Study ID: NCT02702141

ARN-810 for Locally Advanced or Metastatic Breast Cancer
A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Investigator: Hannah Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01823835

MOXR0916 for Locally Advanced Or Metastatic Solid Tumors
A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of MOXR0916 Administered Intravenously As A Single Agent To Patients With Locally Advanced Or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Advanced Solid Tumors;    Status: Recruiting;   Study ID: NCT02219724

Ascending Dose Study of FS102 for HER2-Positive Tumors
Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors

Investigator: Gabriela Chiorean, MD;   Conditions: All Solid Tumors;    Status: Recruiting;   Study ID: NCT02286219

MPDL3280A + INCB024360 for Non-Small Cell Lung Cancer
A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer

Investigator: Laura Chow, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02298153

Safety Study of SEA-CD40 in Cancer Patients
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies

Investigator: Andrew L. Coveler, MD;   Conditions: Solid Tumors;    Status: Recruiting;   Study ID: NCT02376699

PF-04518600 for Selected Solid Tumors
A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 In Patients With Locally Advanced Or Metastatic Hepatocellular Carcinoma (Hcc), Melanoma, Clear Cell Renal Cell Carcinoma (Rcc) Or Squamous Cell Head And Neck Cancer (Scchn)

Investigator: John Thompson, MD;   Conditions: Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma , Head & Neck Cancer;    Status: Recruiting;   Study ID: NCT02315066

SGN-CD70A for CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

Investigator: John Thompson, MD;   Conditions: Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma;    Status: Recruiting;   Study ID: NCT02216890

CMB305 for Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Sarcoma, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer;    Status: Recruiting;   Study ID: NCT02387125

Nab-Paclitaxel Chemotherapy + Nivolumab for Pancreatic Cancer, Non Small Cell Lung Cancer and Metastatic Breast Cancer
A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

Investigator: Gabriela Chiorean, MD;   Conditions: Breast Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT02309177

Ramucirumab + Pembrolizumab for Gastric Cancer, Non-Small Cell Lung Cancer, or Bladder Cancer (20151222)
An Open-Label, Multicenter, Phase I Study of Ramucirumab plus Pembrolizumab for Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium

Investigator: Rafael Santana-Davila, MD;   Conditions: Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Transitional Cell Carcinoma;    Status: Recruiting;   Study ID: NCT02443324

Nivolumab for Virus-Associated Tumors
Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects With Virus-Positive and Virus-Negative Solid Tumors

Investigator: Shailender Bhatia, MD;   Conditions: Various Advanced Cancers;    Status: Recruiting;   Study ID: NCT02488759

Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies for Advanced Malignancies
A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab* (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

Investigator: Laura Q.M. Chow, MD;   Conditions: Advanced Cancer;    Status: Recruiting;   Study ID: NCT02554812

Basket Study of Entrectinib (RXDX-101) for Solid Tumors
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Investigator: Gabriela Chiorean, MD;   Conditions: Solid Tumors;    Status: Recruiting;   Study ID: NCT02568267

AGS-16C3F vs. Axitinib for Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Investigator: John A. Thompson, MD;   Conditions: Metastatic Renal Cell Carcinoma;    Status: Recruiting;   Study ID: NCT02639182